Login to Your Account

ASH Roundup

Tuesday, December 13, 2011
• Incyte Corp., of Wilmington, Del., presented further analyses from its pivotal Phase III program for Jakafi (ruxolitinib), which included data showing consistent benefit of the drug over placebo in spleen volume reduction and symptom improvement across subgroups of myelofibrosis patients, as well as an overall survival advantage. Jakafi gained approval for myelofibrosis earlier this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription